Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of ...

Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, "Toripalimab has made significant strides in its ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Junshi Biosciences enters distribution and marketing partnership with LEO Pharma for toripalimab in Europe: Shanghai, China Wednesday, January 22, 2025, 14:00 Hrs [IST] Shanghai J ...

Shanghai-based Junshi Biosciences has announced a partnership with Denmark’s LEO Pharma to distribute and commercialise the ...

China’s Junshi Biosciences yesterday revealed that its wholly-owned subsidiary TopAlliance Bioscience has entered into a ...

Junshi Biosciences SHANGHAI, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical ...

SHANGHAI, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to ...